Daria Hazuda, PhD

Vice President, Infectious Diseases Discovery
Chief Scientific Officer
Cambridge Exploratory Science Center

Daria Hazuda serves as Vice President of Infectious Disease Discovery and Chief Scientific Officer of the MRL Cambridge Exploratory Science Center.

Daria joined the antiviral group as a Senior Research Biochemist at Merck in 1989. She has over 20 years of experience in drug discovery and development with more than one hundred-eighty publications focused primarily on antiviral research in the fields of HIV and HCV. She led the research efforts that identified the first-in class HIV integrase inhibitor Isentress, which was awarded the Prix Galien in 2008, and was responsible for pioneering work on HCV drug resistance. She has been recognized with the Bernie Field Lecture Award, the David Barry DART Achievement Award for HIV Drug Development and is a Fellow of the American Society of Microbiology.

Daria is on the editorial board of the ACS Journal on Anti-Infectives Research and the Journal of Viral Eradication. She is currently on the Scientific Program Advisory Council of the American Foundation for AIDS Research (AMFAR) and the Forum for HCV Collaborative Research.

Daria received her PhD from the State University of New York at Stony Brook and her Bachelor of Science from Rutgers University.



MERCK
INVENTING FOR LIFE